#1 Clinical Trials Search in Europe

Gallium (68Ga) Gozetotide

Gallium (68Ga) Gozetotide is an innovative radiopharmaceutical being studied in clinical trials for prostate cancer. This article will discuss its use in diagnosing and potentially treating metastatic castration-resistant prostate cancer (mCRPC). We’ll explore how this drug works, its potential benefits, and what patients can expect when participating in these trials.

Table of Contents

What is Gallium (68Ga) Gozetotide?

Gallium (68Ga) Gozetotide, also known as 68Ga-PSMA-11 or 18F-DCFPyL, is a radioactive diagnostic agent used in the detection of prostate cancer[1]. It is a type of radiopharmaceutical, which means it’s a drug containing a radioactive substance used for diagnostic or therapeutic purposes.

How Does It Work?

This diagnostic tool works by targeting a specific protein called Prostate-Specific Membrane Antigen (PSMA). PSMA is often found in high amounts on prostate cancer cells. When Gallium (68Ga) Gozetotide is injected into the body, it attaches to these PSMA proteins[1]. The radioactive component of the drug then allows special cameras to detect where the drug has accumulated, potentially revealing the location of prostate cancer cells.

Uses in Prostate Cancer

Gallium (68Ga) Gozetotide is primarily used in a type of imaging test called PSMA-PET scan (Prostate-Specific Membrane Antigen Positron Emission Tomography). This scan is used for several purposes in prostate cancer management:

  • Detecting prostate cancer that has spread to other parts of the body
  • Monitoring for cancer recurrence after initial treatment
  • Assessing the extent of cancer in patients with biochemically recurrent prostate cancer (when blood tests show rising PSA levels after initial treatment)[1]
  • Helping to determine the best treatment options for patients

Administration

Gallium (68Ga) Gozetotide is administered as an intravenous injection. The typical dose ranges from 1.03 to 185 MBq (megabecquerels), which are units used to measure radioactivity[1][2]. After the injection, patients typically undergo imaging within a short period, usually about an hour.

Safety and Side Effects

As with any medical procedure involving radiation, there are some risks associated with Gallium (68Ga) Gozetotide. However, the radiation exposure is generally considered low and the benefits of accurate diagnosis often outweigh the risks. Common side effects are usually mild and may include:

  • Injection site reactions
  • Fatigue
  • Nausea

It’s important to discuss any concerns about side effects with your healthcare provider[2].

Ongoing Research

Gallium (68Ga) Gozetotide is being studied in various clinical trials to further understand its potential uses and benefits. For example, it’s being used in a study called SPLASH, which is evaluating a treatment called 177Lu-PNT2002 for patients with metastatic castration-resistant prostate cancer (mCRPC)[2]. In this study, Gallium (68Ga) Gozetotide is used to identify patients who might benefit from the treatment and to monitor their response.

Another study is using Gallium (68Ga) Gozetotide to help select patients for a clinical trial comparing different treatments for prostate cancer that has recurred after initial therapy[1].

These ongoing studies demonstrate the importance of Gallium (68Ga) Gozetotide in advancing our understanding and treatment of prostate cancer.

Aspect Details
Drug Name Gallium (68Ga) Gozetotide
Primary Use Diagnostic imaging for prostate cancer
Administration Intravenous injection
Dosage Up to 185 MBq (megabecquerels)
Key Benefit Improved detection of prostate cancer lesions
Trial Phase Phase 3
Target Population Men with metastatic castration-resistant prostate cancer (mCRPC)
Primary Endpoint Radiographic progression-free survival (rPFS)

FAQ

  • What is Gallium (68Ga) Gozetotide? Gallium (68Ga) Gozetotide is a radioactive tracer used in prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scans. It helps identify prostate cancer cells that have spread to other parts of the body.
  • How is Gallium (68Ga) Gozetotide used in clinical trials? In these trials, Gallium (68Ga) Gozetotide is used for PSMA PET/CT scans to detect prostate cancer lesions. It helps researchers identify eligible patients and monitor the progression of the disease during treatment.
  • What are the potential benefits of using Gallium (68Ga) Gozetotide? Gallium (68Ga) Gozetotide can provide more accurate imaging of prostate cancer spread compared to conventional methods. This can lead to better treatment planning and monitoring of the disease's progression.
  • Are there any risks associated with Gallium (68Ga) Gozetotide? As with any radioactive tracer, there is a small radiation exposure. However, the benefits of improved cancer detection usually outweigh this risk. Patients should discuss potential risks with their healthcare provider.
  • Who is eligible to participate in these clinical trials? Eligibility criteria vary, but generally include adult males with confirmed prostate cancer, specific PSA levels, and evidence of disease progression. Patients must also meet certain health requirements and be willing to undergo PSMA PET/CT scans.

Ongoing Clinical Trials on Gallium (68Ga) Gozetotide

  • Study Comparing Gallium (68Ga) Gozetotide and Zirconium (89Zr) Girentuximab PET Scans for Detecting Tumors in Patients with Metastatic Renal Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +8

Glossary

  • Metastatic castration-resistant prostate cancer (mCRPC): A type of prostate cancer that has spread beyond the prostate and continues to grow despite treatments that lower testosterone levels.
  • PSMA PET/CT: Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography, an imaging technique that uses radioactive tracers to detect prostate cancer cells throughout the body.
  • Radiopharmaceutical: A drug that contains a radioactive substance used for diagnosing or treating diseases.
  • Androgen deprivation therapy (ADT): A treatment that reduces levels of male hormones (androgens) to slow the growth of prostate cancer.
  • PSA (Prostate-Specific Antigen): A protein produced by the prostate gland. Elevated levels may indicate prostate cancer or other prostate conditions.
  • Biochemical recurrence (BCR): A rise in PSA levels after initial treatment for prostate cancer, which may indicate the cancer is returning.
  • Radiographic progression-free survival (rPFS): The length of time during and after treatment that a patient lives without their cancer spreading or getting worse, as determined by imaging scans.

References

  1. http://clinicaltrials.eu/trial/study-comparing-darolutamide-and-androgen-deprivation-therapy-to-placebo-and-androgen-deprivation-therapy-in-men-with-high-risk-prostate-cancer-recurrence/
  2. http://clinicaltrials.eu/trial/study-on-treating-metastatic-castration-resistant-prostate-cancer-with-177lu-pnt2002-compared-to-abiraterone-or-enzalutamide-for-patients-after-hormonal-therapy/